160080-87-5

Usage

Uses

Used in Pharmaceutical Industry:
D-7-hydroxy-6,8-diiodo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid is used as a pharmaceutical candidate for its potential pharmacological properties. D-7-hydroxy-6,8-diiodo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid's unique structure, including the hydroxy, diiodo, and carboxylic acid groups, may contribute to its biological activities and therapeutic potential. Further research is needed to explore its specific applications and efficacy in medicine.
Used in Drug Development:
D-7-hydroxy-6,8-diiodo-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid is used in drug development for its potential as a lead compound in the discovery of new therapeutic agents. Its unique structural features and potential pharmacological properties make it a promising candidate for further investigation and optimization to develop novel drugs with improved efficacy and safety profiles.

Upstream product

• 50-00-0 formaldehyd 
• 66-02-4 3,5-diiodotyrosine 
• 556-02-5 ?Tyr 

Downstream Products

• 35186-98-2 7-hydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid 
• 765952-45-2 methyl 2-tert-butoxycarbonyl-6,8-diiodo-7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 765952-48-5 ethyl 3-methoxycarbonyl-7-phenylethyl-1,2,3,4-tetrahydroisoquinoline-2-ethanoate 
• 765952-47-4 7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 
• 765952-42-9 methyl 7-phenylethoxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 
• 765952-41-8 methyl 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylate 

Relevant academic research and scientific papers

Exploring the tetrahydroisoquinoline thiohydantoin scaffold blockade the androgen receptor as potent anti-prostate cancer agents

Prostate cancer (PC) is a major cause of cancer-related male death in worldwide and the identification of new and improved potent anti-PC molecules is constantly required. A novel scaffold of tetrahydroisoquinoline thiohydantoin was rationally designed based on the enzalutamide structures and our pre-work, leading to the discovery of a series of new antiproliferative compounds. Several new analogues displayed improved androgen receptor (AR) antagonistic activity, while maintaining the higher selective toxicity toward LNCaP cells (AR-rich) versus DU145 cells (AR-deficient) compared to enzalutamide. In fact, compound 55 exhibited promising in vitro antitumor activity by impairing AR unclear translocation. More importantly, 55 showed better pharmacokinetic properties compared to the compound 1 reported in our pre-work. These results demonstrate a step towards the development of novel and improved AR antagonists.

Synthesis of 7-phenylethoxy-1,2,3,4-tetrahydroiso- quinoline derivatives

Synthesis of 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid derivatives is described, from diiodotyrosine, using a Pictet-Spengler reaction and further O-alkylation of the aromatic ring providing compounds (1) and (2).